Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Massimo Raimondo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3750-1541; OpenAlex author ID A5012699718. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 3, last author 3)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper, 1 trial · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 18

  1. An Analysis of the Clinical Burden and Economic Costs of Venous Thromboembolism During Inpatient Admissions for Pancreatic Cancer in the United States. Co-author DOI 10.1177/10499091251341453↗
  2. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Co-author DOI 10.1016/j.cgh.2024.07.048↗
  3. The Determinants of Inpatient Palliative Care Use in Patients With Pancreatic Cancer. Co-author DOI 10.1177/10499091231218257↗
  4. Pancreatic steatosis on computed tomography is an early imaging feature of pre-diagnostic pancreatic cancer: A preliminary study in overweight patients. Last author DOI 10.1016/j.pan.2021.01.003↗
  5. Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomi… Co-author DOI 10.1055/a-1223-2171↗
  6. The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004-2013: A SEER Analysis. Co-author DOI 10.1080/07357907.2021.1888386↗
  7. A 3-Decade Analysis of Pancreatic Adenocarcinoma After Solid Organ Transplant. Co-author DOI 10.1097/mpa.0000000000001722↗
  8. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. First author DOI 10.1016/j.cgh.2019.07.017↗
  9. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. Co-author DOI 10.1089/pancan.2018.0011↗
  10. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1038/ajg.2016.482↗
  11. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  12. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Last author DOI 10.1016/j.dld.2015.06.015↗
  13. New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. First author DOI 10.1158/1078-0432.ccr-14-2469↗
  14. Polarization gating spectroscopy of normal-appearing duodenal mucosa to detect pancreatic cancer. Co-author DOI 10.1016/j.gie.2014.03.031↗
  15. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Co-author DOI 10.2174/1566524013666131217112921↗
  16. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. First author DOI 10.7150/jca.10094↗
  17. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needl… Co-author DOI 10.1055/s-0033-1344216↗
  18. Diagnostic management of pancreatic cancer. Last author DOI 10.3390/cancers3010494↗

Trials 2

  1. Optical and Biochemical Biomarkers in Early Pancreatic Cancer Principal investigator NCT03404661↗
  2. Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer Principal investigator NCT00851955↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael B. Wallace · 12 shared papers, 2013–2026 · strength 1.41
  2. Frank Lukens · 3 shared papers, 2024–2026 · strength 0.81
  3. Osayande Osagiede · 2 shared papers, 2024–2026 · strength 0.64
  4. Yan Bi · 2 shared papers, 2021–2026 · strength 0.48
  5. Victoria Gómez · 3 shared papers, 2018–2025 · strength 0.39
  6. John Andrew Stauffer · 5 shared papers, 2013–2021 · strength 0.38
  7. Sanne A.M. Hoogenboom · 2 shared papers, 2021–2025 · strength 0.32
  8. Jeanin Elise van Hooft · 2 shared papers, 2021–2025 · strength 0.32
  9. Bhaumik S. Brahmbhatt · 2 shared papers, 2021–2025 · strength 0.30
  10. Douglas W. Mahoney · 3 shared papers, 2015–2025 · strength 0.29
  11. John B. Kisiel · 3 shared papers, 2015–2025 · strength 0.29
  12. Juan E. Corral · 2 shared papers, 2021 · strength 0.28
  13. Ferga C. Gleeson · 2 shared papers, 2020–2025 · strength 0.25
  14. Shounak Majumder · 2 shared papers, 2020–2025 · strength 0.25
  15. Kabir Mody · 2 shared papers, 2018–2021 · strength 0.24
  16. Candice W. Bolan · 2 shared papers, 2018–2021 · strength 0.23
  17. Horacio J. Asbun · 4 shared papers, 2013–2018 · strength 0.23
  18. Pujan Kandel · 2 shared papers, 2018–2021 · strength 0.22
  19. Sushovan Guha · 4 shared papers, 2014–2017 · strength 0.19
  20. Sonal Gandhi · 1 shared paper, 2025 · strength 0.17
  21. Jaime de la Fuente · 1 shared paper, 2025 · strength 0.17
  22. Megan M.L. Engels · 1 shared paper, 2025 · strength 0.17
  23. Dhruv Sarwal · 1 shared paper, 2025 · strength 0.17
  24. Eric J. Vargas · 1 shared paper, 2025 · strength 0.17
  25. Derk C.F. Klatte · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.